Literature DB >> 8808165

Natural vs synthetic surfactants in neonatal respiratory distress syndrome.

H L Halliday1.   

Abstract

This review examines the 11 randomised clinical trials that have compared different surfactant preparations. Seven trials, enrolling 2488 infants with respiratory distress syndrome (RDS), compared the natural surfactant beractant (Survanta) with the synthetic surfactant colfosceril palmitate (Exosurf Neonatal). Infants treated with beractant had lower oxygen requirements for at least 3 days than those treated with colfosceril palmitate. The infants treated with beractant also had lower risks of neonatal mortality [odds ratio (OR) 0.81; 95% confidence interval (CI) 0.65 to 1.01], retinopathy of prematurity (OR 0.81; 95% CI 0.66 to 0.99), and the combined endpoint of death or bronchopulmonary dysplasia (OR 0.86; 95% CI 0.75 to 0.99), compared with those treated with colfosceril palmitate. Calf lung surfactant extract (CLSE; Infasurf), another natural surfactant, has been compared with colfosceril palmitate in 2 studies: in one as prophylaxis and in the other as rescue therapy. Similar, although nonsignificant, advantages were found for the natural surfactant compared with the synthetic surfactant. In 6 of these 9 trials there was a significant reduction in the odds of pulmonary air leaks (OR 0.53; 95% CI 0.41 to 0.64) for infants treated with natural compared with synthetic surfactants. In 7 trials (3554 infants) comparing natural and synthetic surfactants to treat RDS (6 comparing beractant and colfosceril palmitate, and one CLSE and colfosceril palmitate), there was a significantly reduced risk of neonatal mortality (OR 0.80; 95% CI 0.66 to 0.97) with natural compared with synthetic surfactant treatment. In 2 further trials, different natural surfactant preparations have been compared. Reduced oxygen needs for 24 hours after treatment were found for CLSE and Curosurf (porcine-derived lung surfactant, PLS) when each was compared with beractant. Apparent longer term benefits from these surfactants were not statistically proven. Further trials are needed to be certain of the differences between the various surfactant preparations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8808165     DOI: 10.2165/00003495-199651020-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  31 in total

1.  Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity.

Authors:  T R Tubman; S J Rankin; H L Halliday; S S Johnston
Journal:  Biol Neonate       Date:  1992

2.  Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. The American Exosurf Neonatal Study Group I.

Authors:  D Stevenson; F Walther; W Long; M Sell; T Pauly; A Gong; D Easa; A Pramanik; M LeBlanc; E Anday
Journal:  J Pediatr       Date:  1992-02       Impact factor: 4.406

Review 3.  Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome.

Authors:  L R Wiseman; H M Bryson
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

4.  Surfactant replacement therapy.

Authors:  H L Halliday
Journal:  Pediatr Pulmonol Suppl       Date:  1995

5.  Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group.

Authors: 
Journal:  Pediatrics       Date:  1988-11       Impact factor: 7.124

6.  A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs.

Authors:  J J Cummings; B A Holm; M L Hudak; B B Hudak; W H Ferguson; E A Egan
Journal:  Am Rev Respir Dis       Date:  1992-05

7.  Dry artificial lung surfactant and its effect on very premature babies.

Authors:  C J Morley; A D Bangham; N Miller; J A Davis
Journal:  Lancet       Date:  1981-01-10       Impact factor: 79.321

8.  Comparison of surface properties and physiological effects of a synthetic and a natural surfactant in preterm rabbits.

Authors:  J D Corcoran; P Berggren; B Sun; H L Halliday; B Robertson; T Curstedt
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-11       Impact factor: 5.747

9.  A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.

Authors:  J D Horbar; L L Wright; R F Soll; E C Wright; A A Fanaroff; S B Korones; S Shankaran; W Oh; B D Fletcher; C R Bauer
Journal:  J Pediatr       Date:  1993-11       Impact factor: 4.406

10.  Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.

Authors:  C P Speer; O Gefeller; P Groneck; E Laufkötter; C Roll; L Hanssler; K Harms; E Herting; H Boenisch; J Windeler
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-01       Impact factor: 5.747

View more
  7 in total

Review 1.  Calfactant: a review of its use in neonatal respiratory distress syndrome.

Authors:  S V Onrust; M Dooley; K L Goa
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

Review 2.  Current perspectives on the drug treatment of neonatal respiratory distress syndrome.

Authors:  D G Sweet; H L Halliday
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

3.  Events before the diagnosis of a pneumothorax in ventilated neonates.

Authors:  M Watkinson; I Tiron
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-11       Impact factor: 5.747

4.  A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.

Authors:  H Walti; M Monset-Couchard
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

5.  [Not Available].

Authors: 
Journal:  Paediatr Child Health       Date:  2005-02       Impact factor: 2.253

6.  Recommendations for neonatal surfactant therapy.

Authors: 
Journal:  Paediatr Child Health       Date:  2005-02       Impact factor: 2.253

7.  Lysophosphatidylcholine abrogates the CR1 preserving effect of surfactant on quartz-exposed human granulocytes.

Authors:  G Zetterberg; T Curstedt; J Lundahl; A Eklund
Journal:  Inflammation       Date:  1999-04       Impact factor: 4.092

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.